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ISSNBackground: The HIV-1 envelope is covered with glycans that provide structural integrity
and protect conserved regions from host antibody responses. However, these glycans are
often the target of broadly neutralizing antibodies (bNAbs) that emerge in some HIV-
infected individuals. We aimed to determine whether antiglycan IgG antibodies are a
general response to HIV-1 infection or specific to individuals who develop bNAbs.
Methods: IgG binding to glycans was assessed using arrays that contained 245 unique
components including N-linked carbohydrates, glycolipids, and Tn-peptides. Sera from
20 HIV-negative and 27 HIV-positive women (including 12 individuals who developed
bNAbs) were profiled longitudinally. HIV-1 gp120 proteins were used to compete for
binding to the array.
Results: Antiglycan IgG antibodies fluctuated over a 3-year period, irrespective of HIV
infection.However, HIV-positive individuals had elevatedbinding to 40 components on the
array that included Man8, Man9, Tn-peptides, heat shock protein, and glycolipids. Compe-
tition experiments confirmed that a proportion of these glycan-binding IgG antibodies were
HIV-1-specific, some of which were higher in individuals who developed bNAbs.
Conclusions: HIV-1 infection is associated with elevated levels of IgG antibodies to
specific glycans. Furthermore, some antiglycan IgG antibodies were more abundant in
individuals with bNAbs, suggesting a unique phenotype that may be informative for HIV
vaccine design. Copyright  2017 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2017, 31:2199–2209Keywords: broadly neutralizing antibodies, glycan arrays, high mannose
N-linked glycans, HIV-1 infection, Tn-peptidesIntroduction
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which typically target gp120 and persist throughout
infection [2]. In a subset of HIV-infected individuals,
broadly neutralizing antibodies (bNAbs), capable of
neutralizing a large number of HIV strains, develop after
2–3 years of infection [2]. Understanding the factors
that regulate bNAb development is a major research
endeavour.
The trimeric HIV envelope glycoprotein is heavily
glycosylated with between 25 and 30 N-linked
glycosylation sites that account for half of its molecular
mass, known as the glycan shield [3,4]. Although glycans
are attached to the viral envelope through the host
cell glycosylation pathways, they undergo limited
processing, resulting in inefficiently trimmed glycans
[5]. The glycan shield on trimeric gp120 is mostly
comprised of densely packed high mannose, particularly
Mana1–2Man terminating glycans such as Man6–
9GlcNAc2, and complex N-linked glycans, although
some O-linked glycans do occur [3,4,6–8]. In addition
to protecting immunogenic sites on the virus, these
glycans are also essential for glycoprotein folding and are
thus often conserved [3–5].
A significant number of bNAbs target glycan-rich
epitopes on the HIV envelope [9]. The N332 supersite
on the V3 and V4 loops includes Man7–9 and are targeted
by 2G12 and some of the PGTantibodies (PGT125–131
and PGT135), whereas complex type glycans (A2, N2,
and NA2) are targeted by PGT121–123 [10,11]. The
N160, N156, and/or N173 sites of V2 region have high
mannose N-linked glycans and sialylated N-linked
glycans, which are bound by PG9/PG16 and the
CAP256-VRC26 lineage [12–14]. High mannose N-
linked glycans have also been observed at the gp120-gp41
interface (targeted by 8ANC195 and 35O22) and CD4-
binding sites (targeted by HJ16 and PGV04) [3,9,15–17].
Despite the identification and characterization of a
number of glycan-binding monoclonal bNAbs, the
polyclonal serum antiglycan antibody responses to HIV
infection in humans have not been well studied.
Glycan arrays have been developed to study the glycan-
binding profiles of antibodies and have proven to be
particularly useful in determining the types of glycan
structures that are bound by HIV-1 bNAbs [10,11,18–
25]. In addition, the antiglycan antibody responses in sera
of nonhuman primates after Ad5hr-simian immunodefi-
ciency virus (SIV) vaccination and SIV infection [26] and
HIV vaccine responses in rabbits have been assayed on
arrays [20,27,28]. Here, we studied serum antiglycan IgG
antibody profiles of HIV-negative and HIV-positive
individuals, including those who develop bNAbs, over 3
years of infection. Our aim was to determine whether
elevated levels of serum antiglycan IgG antibodies are
observed during HIV infection or unique to individuals
who make bNAbs. Copyright © 2017 Wolters Kluwer HMethods
Serum samples and ethics statement
Sera from 47 South African Black women (27 HIV-
positive and 20 HIV-negative) taken at four time-points
(yearly for 3 years and, when available, prior to infection)
were obtained from the Centre for the AIDS Programme
of Research in South Africa (CAPRISA) 002 Acute
Infection Study [29] and the 004 Tenofovir Gel Trial [30]
cohorts. Among the 27 HIV-positive individuals, 12
developed bNAbs and 12 did not develop bNAbs, despite
being infected for at least 2 years and having similar
antigenic loads (Supplementary Table 1, http://
links.lww.com/QAD/B157) [31]. Sera were tested
against a panel of 18 viruses comprising 6 subtype A, 6
subtype B, and 6 subtype C viruses. Individuals with
bNAbs were capable of neutralizing 33–94% (median
53%) of the panel, whereas those without bNAbs
neutralized only 0–6%. Three individuals whose sera
neutralized 17–22% of the panel viruses were termed
intermediate neutralizers. The HIV-positive samples were
selected based on neutralization breadth and matched for
viral load. Samples from 20 HIV-negative individuals
were used as controls to assess normal fluctuations in
glycan-binding over a 3-year period. Control reference
serum, consisting of pooled human sera, used to assess
reproducibility of the arrays, was purchased from Valley
Biomedical Products and Services (Winchester, Virginia,
USA). All human serum samples were heat-inactivated
for 30 min in a 568C water bath prior to binding on the
glycan arrays. Similar experiments using samples from
macaques showed no inhibitory effect on antibody
function or antiglycan antibody profiles [26,32]. All time-
points from the same individual were run on the same day
to minimize intraindividual variability, and samples from
individuals with and without bNAbs were intermixed to
minimize experimental biases. In addition, all samples
were run in duplicate and averaged. This study received
ethics clearance from the University of the Witwatersrand
(M080470 and M111104). The CAPRISA Acute
Infection study in adult women received ethical approval
from the Universities of KwaZulu-Natal (E013/04),
Cape Town (025/2004), and the Witwatersrand
(MM040202), and informed consent was obtained from
all study participants.
Monoclonal antibodies
Seven well characterized bNAbs were used to assess the
ability of the glycan arrays to detect HIV-specific glycan-
binding. PG16 and 2G12 were obtained from the NIH
AIDS Reagent Program. PGT121, PGT125, PGT126,
PGT128, and PGT130 were provided by IAVI’s
Neutralizing Antibody Center (Scripps Research Insti-
tute, La Jolla, California, USA).
Glycan arrays
Glycan arrays were composed of 337 components (of
which 245 were unique structures, many of which wereealth, Inc. All rights reserved.
Glycan-binding IgG antibodies Scheepers et al. 2201printed at multiple densities on the array surface), including
N-linked carbohydrates, glycolipids, and glycopeptides
(Supplementary Table 2, http://links.lww.com/QAD/
B157). Included in the array were ten controls (BSA, HSA,
linkers, and fluorochromes) that were used to assess
technical reproducibility and were excluded from down-
stream analysis. The arrays were generated as previously
described [26], with the exception of the addition of a
washable fluorescent dye, DyLight649 (0.7 mg/ml; Ther-
moScientific, Waltham, Massachusetts, USA) to the print
buffer as an indicator of successful liquid deposition and
spot morphology. Triton X-100 concentration was
reduced to 0.0001% instead of 0.006% to produce smaller
spots allowing additional glycans to be spotted onto the
plate. The array format and binding assay were analyzed for
reproducibility and validated with numerous antibodies
and lectins as previously described [33–37]. All array
experiments were done using sera diluted 1 : 50 in the
absence of calcium. Other studies using these arrays have
ruled out competition by lectins, such as mannose-binding
lectin (MBL), under these conditions (unpublished data).
Slides were scanned at 10 mm resolution with a Genepix
4000A microarray scanner (Molecular Devices Corpora-
tion, Sunnyvale, California, USA) and analyzed with
Genepix Pro 6.0 software as previously reported [33].
gp120 competition assay
To determine if glycan-binding profiles were HIV-
specific, sera with high Man8 binding levels were
incubated with purified monomeric ConC gp120
(100 mg/ml) or PBS alone at room temperature for
15 min. Monomeric ConC gp120 was expressed as
described in Gray et al. [38] and purified using a Galanthus
Nivalis lectin (Stratagene, La Jolla, California, USA). Sera
incubated with or without gp120 were run on the same
glycan array slide to minimize variability. A total of three
wells (six replicate spots) were analyzed.
Statistical and data analysis
All fold-change differences were calculated based on
relative fluorescence unit (RFU) binding. Pearson
correlations were used to calculate the coefficient of
determination (r2) of glycan-binding between and within
individuals. Two methods were used to assess levels of
glycan-binding in HIV-positive samples relative to HIV-
negative samples. The first method identified array
components with binding levels at least two-fold higher
than those observed in the HIV-negative samples and
present in at least two HIV-infected individuals. In the
second method, we identified components with at
least two-fold increased binding over two consecutive
time-points in postinfection samples in at least two
individuals compared to matched preinfection samples.
Two-sampled t tests were used to compare the binding
profiles of gp120 or PBS-treated sera in the gp120
competition assay and between the individuals who made
bNAbs and those who did not. The resulting P values
were corrected for multiple testing using a Bonferroni Copyright © 2017 Wolters Kluwecorrection and P values 0.05 or less were considered
significant.Results
Detection of monoclonal antibody binding on
glycan arrays
Seven well characterized monoclonal antibodies (mAbs)
with broadly neutralizing activity were used to assess the
array’s ability to detect HIV-specific glycan-binding.
These mAbs targeted high mannose N-linked glycans and
complex glycans on the V2 and V3 loops of gp120
[10,11,24,39,40]. A cut-off of at least 3000 (log211)
relative fluorescence values (RFUs) was used in order to
compare our data to a previously published study [11].
Six of the seven mAbs bound to at least two glycans
(Fig. 1) confirming previous reports [10,11,24,39,40].
The only mAb with no binding was PG16, which is
known to target a trimer-specific epitope and has
previously failed to bind on arrays [17]. The mAb
2G12 and the PGT antibodies, except PGT121, bound
high mannose N-linked glycans Man8 and Man9 to
varying levels. PGT121 bound NA2 (other glycans A2,
A2F, and N2 previously associated with PGT121 [10,11]
were not part of this array). In addition, we found
binding to thyroglobulin by PGT125, PGT128, and
PGT130, whereas fatty acid-binding protein (FABP),
ManT (branched Man3 glycan), and galactose-a (Gal-a)
were recognized by single mAbs. On the basis of these
results, we concluded that the array used in this study
was capable of capturing HIV-specific glycan-binding
antibodies.
Natural fluctuations in antiglycan IgG antibodies
over 3 years
To identify changes associated with HIV infection, it was
necessary to first define natural fluctuations in serum
antiglycan IgG antibodies in HIV-negative individuals.
Previous longitudinal studies of human sera on glycan
arrays have been limited to 1–3 months [36], and because
bNAbs take years to develop, we aimed to understand
natural fluctuations in glycan-binding IgG antibodies
over a longer timeframe. We therefore profiled 80 serum
samples from 20 HIV-negative individuals (from the
CAPRISA 002 and 004 cohorts) collected yearly for 3
years (time-points labeled as 0, 1, 2, and 3 years).
As might be expected, we observed greater fluctuations
over 3 years than seen in previous studies (data not shown)
[36,41]. For all HIV-negative samples, 10% of the glycans
varied by 2.6-fold (typically used as a cut-off for healthy
individuals [36]), 3% by 4-fold, and only 0.5% showed
more than 10-fold changes. Fluctuations varied consid-
erably between individuals with some (e.g. CAP11)
showing fewer glycan changes between time-points, andr Health, Inc. All rights reserved.
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Fig. 1. Monoclonal antibody (mAb) glycan-binding profiles. (a) Heatmap of binding by each mAb on the glycan array. Shown are
the log2-binding values of the seven mAbs for all glycans on the array. (b) Table comparing glycan-binding profiles from this array
to previous studies. Listed are the glycans that had RFU-binding values at least 3000 (log211, the cut-off used in previous studies).
(c) Glycan-binding profiles of all seven mAbs for all glycans with RFU-binding at least 3000. Shown are the RFU-binding values for
each of the mAbs tested for all eight glycans observed with binding at least 3000 on this array. RFU, relative fluorescence unit.others (CAP39 and CAP54) with more drastic changes
(Fig. 2a). By comparison, HIV-positive individuals
showed similar fluctuations over time including some
with more drastic changes (Fig. 2b). Despite these
fluctuations, the overall IgG antibody glycan-binding
profiles from the same individual at different time points
were highly correlated based on Pearson correlations,
with coefficient of determination (r2) values typically at
least 0.9, irrespective of HIV infection. This is in contrast
to correlations seen between different individuals, which
showed more variation, where r2 values were typically 0.8
or less (Fig. 2c).
Although substantial changes could be observed in some
individuals at certain time-points irrespective of HIV
infection, antiglycan antibody signals generally oscillated
rather than continually increased or decreased throughout
the 3 years of study. This result suggests a fluctuation
about a steady-state level for essentially all the antibody
populations measured in these individuals. Thus, we
concluded that comparing a single time-point could
result in a high proportion of false-positives, and that Copyright © 2017 Wolters Kluwer Hlongitudinal sampling was necessary to accurately




We devised two methods that used data from HIV-
negative samples to identify responses associated with
HIV-1 infection. In the first method, we compared 88
longitudinal samples from 27 HIV-positive individuals to
80 longitudinal samples from the 20 HIV-negative
individuals. Binding needed to be at least two-fold
higher than the highest level seen within the HIV-
negative individuals and observed in at least two HIV-
positive individuals to be considered elevated. In the
second method, we focused on changes relative to
preinfection, which were only available for 11 of the 27
HIV-infected individuals, selecting array components
with at least two-fold increased binding in two
consecutive time-points (to account for temporal
oscillations) in postinfection samples.ealth, Inc. All rights reserved.
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Fig. 2. Fluctuations in longitudinal antiglycan serum IgG. (a) Longitudinal fluctuations in HIV-negative individuals. Shown are
fold-change differences in longitudinal serum IgG antibodies compared to year 0 for 15 of 20 HIV-negative individuals for whom
all four time-points were available. Each line represents a different glycan spotted on the array. (b) Longitudinal fluctuations in HIV-
positive individuals. Shown are the fold-change differences in longitudinal serum IgG antibodies compared to matched
preinfection samples for nine of 27 HIV-infected individuals for which all four time-points were available, where each line
represents a different glycan. (c) Correlation of longitudinal samples within and across individuals. Shown are the r2 values of
Pearson correlations comparing the RFU values of all glycans on the arrays for each of the four time-points for each of the
participants shown in (a) and (b). The heat map is ordered so that all four time-points per individual are next to each other (time-
points not labeled), with the HIV-positive individuals in the bottom right corner. The correlations shown in the diagonal (mostly in
red) represent each time-point within an individual, those outside the diagonal in gray represent the correlations compared across
individuals.A combination of these two methods identified 40 (out of
245) array components that were elevated in HIV-
positive samples, including high mannose N-linked
glycans, Tn-peptides, glycolipids, glycoproteins, Tf-
peptides, and Lewis antigens (Supplementary Table 3,
http://links.lww.com/QAD/B157). Most (36/40, 90%)
were elevated in postinfection samples compared to
matched preinfection samples. Nine out of the 40
components were identified using both methods, and
included Man8, 4 Tn-peptides [Ac-A-Tn(Thr)-S-G, Ac-
S-Tn(Thr)-Tn(Thr)-G, Ac-S-Tn(Thr)-G-G, and Ac-P-
Tn(Thr)-T-G], 2 glycolipids (GT2 and GT3), heat shock
protein (HSP), and Fuc-b (Fig. 3). The highest levels of
binding against Man8 were observed at 3 years
postinfection, with two individuals having 15-fold and Copyright © 2017 Wolters Kluwe11.5-fold higher binding than the HIV-negative samples,
respectively (Fig. 3a). In addition, these values were 6–8-
fold higher than the median of 220 previously studied
healthy individuals from the United States [42]. Other N-
linked high mannose glycans (Man5 and Man9), identified
using only the first method, also showed very high levels
of binding at 3 years postinfection, 53-fold and 7-fold,
respectively. Increased binding to the Tn-peptides were
observed throughout HIV infection, with the exception
of Ac-P-Tn(Thr)-T-G, in which increased binding was
mostly observed at 1 year postinfection (Fig. 3e).
Likewise, binding against the two glycolipids and Fuc-
b were observed throughout infection, whereas elevated
binding to HSP was mostly observed at 1 and 3 years
postinfection (Fig. 3f–i).r Health, Inc. All rights reserved.
2204 AIDS 2017, Vol 31 No 16
Fig. 3. Longitudinal glycan-binding profiles during HIV-1 infection. Shown are the log2-binding values for all serum samples.
HIV-negative and preinfection (green), 1 year postinfection (ypi, in yellow), 2 years postinfection (orange), and 3 years
postinfection (red). Each HIV-positive individual is shown using a different symbol. Tn-1 refers to Ac-A-Tn(Thr)-S-G, Tn-2 Ac-
S-Tn(Thr)-Tn(Thr)-G, Tn-4 Ac-S-Tn(Thr)-G-G, and Tn-6 Ac-P-Tn(Thr)-T-G.
Fig. 4. Reduced glycan-binding following gp120 incubation.
Shown are log2-binding values for 3 year postinfection sera
from eight HIV-1-infected individuals incubated with PBS
(gray) or gp120 (purple) prior to binding on the glycan array.
The mean RFU fold-change differences (FCs) associated with
each glycan are shown above the plot. Tn-3 refers to Ac-S-
Tn(Thr)-A-G. RFU, relative fluorescence unit.Competition with gp120 suggests some
glycan-binding IgG antibodies to be HIV-specific
Since increased glycan-binding may be due to hyper-
gammaglobulinemia associated with HIV infection, we
used a competition assay to determine what proportion of
these antibodies was HIV-specific. Three-year postinfec-
tion sera from eight HIV-positive individuals (highlighted
in Supplementary Table 1, http://links.lww.com/QAD/
B157), with high levels of binding to Man8, found on the
HIV-1 trimer [3], were incubated with the HIV
glycoprotein gp120 prior to glycan array binding
(data from NA3, NA4, NGA2B, Sialyl LeA, or the
Tf-peptides were not available in this experiment). As a
control, gp120-incubated sera showed a 21.4-fold
reduction in median binding to gp120 compared to
the PBS-incubated sera (Fig. 4). We saw a 10.9-fold
decrease in binding to Man8 following gp120 incubation, Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
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Tn-3 [Ac-S-Tn(Thr)-A-G], and heparin. These data
suggested that at least a proportion of these glycan-
binding IgG antibodies are HIV-specific.
Unique HIV-specific antiglycan IgG profiles in
individuals who develop broadly neutralizing
antibodies
To determine if the elevated levels of binding observed
during HIV infection were unique to individuals who
developed bNAbs, the binding levels for the 40 array
components that were elevated during infection were
compared between the individuals that made bNAbs and
individuals who did not develop bNAbs (Supplementary
Table 1, http://links.lww.com/QAD/B157). For this
analysis, we used samples from 10 bNAb and 11
nonbNAb individuals at 3 years postinfection (Fig. 5).
Although there were no statistically significant differences
between the two groups, individuals who developed
bNAbs tended to have higher levels of glycan-binding
antibodies, particularly to some high mannose (Man3 and
NA4), Tn-peptides (Tn-1, Tn-2, Tn-3, and Tn-6), and
HSP90. These data suggest that individuals who develop
bNAbs may have a unique serological profile that could
be informative for vaccine design.Discussion
In this study, we used glycan microarray technology to
profile IgG responses over 3 years of HIV-1 infection. We
observed an increase in glycan-binding antibodies upon
infection to 40 components on the array, including high
mannose N-linked glycans, Tn-peptides, and glycolipids,
some of which were confirmed to be HIV-specific
following a reduction in binding after gp120 incubation.
Furthermore, individuals who made bNAbs tended to
have elevated levels of glycan-binding compared to those
who did not, despite chronic HIV infection. This study is
the most comprehensive analysis of antiglycan IgG
antibody responses induced by HIV infection and
highlights a potentially unique glycan-binding profile
in individuals who develop bNAbs.
Since glycans are targeted by the human immune system,
we first profiled serum IgG antibodies in HIV-negative
individuals with similar demographics over a 3-year time
frame to determine baseline antiglycan IgG antibody
levels. These profiles were highly correlated within an
individual at different time-points, with antibody
subpopulations fluctuating about a steady state, suggesting
a highly co-ordinated and controlled response to
antigenic stimuli. As expected, these fluctuations varied
considerably from one individual to another and were
greater than those observed in earlier studies over a short
time period [36,41]. This analysis highlights the
importance of having matched controls when studying
antiglycan responses to infection. Copyright © 2017 Wolters KluweTwo different approaches were devised to account for
natural glycan-binding variation, which identified a
number of IgG responses that were the result of HIV
infection. Antibodies to high mannose glycans, such as
Man8, were one of the most noteworthy responses, with
certain individuals producing exceptionally high signals
compared to HIV-negative control individuals. In addi-
tion, these antibodies were partially depleted by pre-
incubation with gp120, providing support that they are
HIV-specific. Responses to high mannose N-linked
glycans tended to occur during chronic infection, with
the highest levels of binding seen at 3 years postinfection.
This time frame is in line with the development of bNAbs,
although responses to Man8 and Man9 did not show a
significant association with breadth possibly because these
are also targeted by strain-specific antibodies.
In addition to high mannose antibodies, we observed HIV-
associated responses to Tn-peptides, glycolipids, glyco-
proteins, Lewis antigens, Tf-peptides, and other array
components, some of which were also higher among
individuals with bNAbs. Increased binding to Tn-peptides
has also been observed following SIV vaccination and SIV
infection using this same array [26]. Tn-peptides are
precursors of O-linked glycans, and in normal mammalian
cells the Tn-portion of the O-linked glycans are masked
during the glycosylation pathway. However, in HIV
infection, the normal glycosylation pathways are altered
revealing the Tn-portion of these O-linked glycans on the
glycan shield potentially rendering them more immuno-
genic [26]. Interestingly, anti-Tn-peptide antibodies have
been associated with the neutralization of HIV-1 by
preventing fusion of the virus into infected cells [43,44].
Furthermore, a recent study has revealed how O-linked
glycans on viral surfaces are used to initiate immune
responses at mucosal surfaces [45].
Similarly, other glycans that we identified have previously
been associated with HIV. Ganglioside glycosphingolipids
are found on the HIV-1 envelope and have been
associated with the uptake of HIV-1 into mature
dendritic cells [46–49]. These glycolipids attach to the
cellular receptor Siglec-1 enabling the incorporation of
HIV-1 into the dendritic cell and the subsequent transfer
to CD4þ T cells [49]. Thyroglobulin (which was also
bound by three of the PGT mAbs) is a glycoprotein
produced by the thyroid gland that is dysregulated in
HIV-infected individuals [50–54]. Thyroglobulin is
highly glycosylated and binds very strongly to ConA,
suggesting that the binding noted in this array may be
through high mannose. Finally, heparin has previously
been observed to inhibit viral infectivity including HIV-
1, and thus its elevation among those with bNAbs is of
interest [55–58].
HIV-1 infection has been associated with a wide range of
B-cell dysfunctions, including hypergammaglobulinemia
(increased levels of circulating IgG), malignancies,r Health, Inc. All rights reserved.
2206 AIDS 2017, Vol 31 No 16
Fig. 5. Differences in glycan-binding between individuals with and without bNAbs. Shown are the log2-binding values at 3 years
postinfection for the individuals who developed bNAbs (n¼10) compared to those who did not develop bNAbs (n¼ 11) despite
chronic HIV infection, for each of the 40 array components that were elevated during HIV infection. Tn-1 refers to Ac-A-Tn(Thr)-S-
G, Tn-2 Ac-S-Tn(Thr)-Tn(Thr)-G, Tn-3 Ac-S-Tn(Thr)-A-G, Tn-4 Ac-S-Tn(Thr)-G-G, Tn-5 Ac-S-Tn(Thr)-S-G, Tn-6 Ac-P-Tn(Thr)-T-G,
Tn-7 Ac-Tn(Ser)-Tn(Ser)-Tn(Ser)-G, Tf-1 DTVPLPTAHGTSASSTG, Tf-2 DTVPLP-TF(Thr)-AHGTSASSTG, and Tf-3 DTVPLPTAHGT-
TF(Ser)-ASSTG. bNAbs, broadly neutralizing antibodies.exhaustion, an increase in subsets of B cells not found in
healthy individuals, and polyclonal activation [1,59,60].
Although we observed a number of changes in HIV-
infected individuals, the overall IgG antibody profiles and Copyright © 2017 Wolters Kluwer Hthe average signals on the array were largely unchanged
within a given individual before and after acquiring HIV
infection. Therefore, the changes we identified using our
two strategies are not simply a result of global changes inealth, Inc. All rights reserved.
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production, but rather a specific response to HIV
infection. It is possible that greater changes might be
observed if all antibodies were assessed and not just those
that bind glycans.
The study had some limitations. First, we were only able
to assess the HIV specificity of antibodies using gp120 and
thus would not have detected glycan-binding antibodies
to epitopes in gp41 or those present only on the trimeric
envelope structure. In addition, only samples with high
levels to Man8 were used in the gp120 competition assay
and not those with high levels to other array components.
It is likely therefore that we have underestimated the
proportion of glycan-binding IgG antibodies that are
HIV-specific. Second, we used stringent criteria to
identify HIV-associated IgG responses. Although our goal
was to minimize false-positives, this approach could have
missed HIV-associated responses that occurred infre-
quently or were below our cut-off. Third, the array
contained only a small fraction of the glycans found in the
human glycome and thus some important responses may
not have been detected. Lastly, the comparison of
individuals who develop bNAbs to those who do not may
be limited by our sample size; increased numbers may
show more statistically significant results.
Nonetheless, this study is the first to highlight natural
fluctuations in a diverse spectrum of glycan-binding IgG
antibodies over a 3-year time frame in healthy and HIV-
infected individuals. Through this, we have shown that
HIV induced glycan-binding antibodies against N-linked
glycans, which are known to be targets of bNAbs, but also
against O-linked glycans and glycolipids, whose role in
the HIVenvelope trimer is less clear. Since the responses
to N-linked high mannose glycans were seen later in
infection, whereas responses to Tn-peptides and glyco-
lipids were seen constantly throughout infection, further
investigation into these glycans may be warranted.Acknowledgements
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